Prapti A. Patel, Fieke Hoff, Andrew J. Belli, Eric Hansen, Courtney Anderson, Anna Barcellos, Laura L. Fernandes, Heidi Foss, Ming He, Molly Schulte, Ching-kun Wang
Research matters
When you’re focusing on the future of cancer care, it helps to start with a clear and accurate picture of the present.
Prapti A. Patel, Yazan F. Madanat, Andrew J. Belli, Eric Hansen, Heidi Foss, Molly Schulte, Ching-Kun Wang
We investigated the outcomes of patients treated with venetoclax based combination therapies in a large cohort of patients in the real-world setting. Survival differences were observed in the different treatment arms with Ven/LDAC having the shortest OS and ven/dac and ven/HMA having comparable survival rates.
Derman BA, Belli AJ, Wang C-K et al.
Awan FT, Belli AJ, Hansen E et al.
Kansagra A, Hansen E, Belli AJ et al.
Data from 1719 patients was used to understand the underlying patient characteristics and optimal treatment sequence for patients with functional high risk disease in multiple myeloma. Patients with cytogenetic high-risk received first line SCT that provided the longest TTNT as compared to other treatments.
A total of 1663 patients treated for DLBCL after 2016 were included in this retrospective analysis to understand treatment patterns and highlight clinical characteristics of potentially eligible patients who do not undergo CAR-T treatment.
Donna R. Rivera, Henry J. Henk, Elizabeth Garrett-Mayer, Jennifer B. Christian, Andrew J. Belli, Suanna S. Bruinooge, Janet L. Espirito, Connor Sweetnam, Monika A. Izano, Yanina Natanzon, Nicholas J. Robert, Mark S. Walker, Aaron B. Cohen, Marley Boyd, Lindsey Enewold, Eric Hansen, Rebecca Honnold, Lawrence Kushi, Pallavi S. Mishra Kalyani, Ruth Pe Benito, Lori C. Sakoda, Elad Sharon, Olga Tymejczyk, Emily Valice, Joseph Wagner, Laura Lasiter, Jeff D. Allen
COTA participated in the FOCR pilot project to evaluate the performance of real-world overall survival (rwOS) from EHRs to a previous randomized controlled trial in NSCLC. These two research papers outline the details of this collaboration in validating endpoints in the real-world setting.
Kansagra A, Derman B, Belli A et al.
Lasiter L, Baxi S, Belli AJ, et al.
